ALL-CAUSE TREATMENT DISCONTINUATION FOR OLANZAPINE COMPARED TO OTHER ANTIPSYCHOTICS IN THE TREATMENT OF SCHIZOPHRENIA: A META-ANALYSIS

被引：0
|
作者：
Soares-Weiser, K. [1 ]
Bechard-Evans, L. [1 ]
Lawson, A. H. [2 ]
Davis, J. [3 ]
Ascher-Svanum, H. [2 ]
机构：
[1] Enhance Reviews Ltd, London, England
[2] Eli Lilly & Co, Indianapolis, IN 46285 USA
[3] Univ Illinois, Chicago, IL USA
来源：
VALUE IN HEALTH | 2010年 / 13卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)72510-9
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A106 / A106
页数：1
相关论文
共 50 条
  • [31] Association of sulphonylurea treatment with all-cause and cardiovascular mortality: A systematic review and meta-analysis of observational studies
    Forst, Thomas
    Hanefeld, Markolf
    Jacob, Stephan
    Moeser, Guido
    Schwenk, Gero
    Pfuetzner, Andreas
    Haupt, Axel
    DIABETES & VASCULAR DISEASE RESEARCH, 2013, 10 (04): : 302 - 314
  • [32] Cardiovascular events and all-cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: A Bayesian meta-analysis of survival data
    Bain, Steve
    Druyts, Eric
    Balijepalli, Chakrapani
    Baxter, Carl A.
    Currie, Craig J.
    Das, Romita
    Donnelly, Richard
    Khunti, Kamlesh
    Langerman, Haya
    Leigh, Paul
    Siliman, Gaye
    Thorlund, Kristian
    Toor, Kabirraaj
    Vora, Jiten
    Mills, Edward J.
    DIABETES OBESITY & METABOLISM, 2017, 19 (03): : 329 - 335
  • [33] Is survival after a diagnosis of cancer influenced by schizophrenia and/or psychosis? A meta-analysis of all-cause mortality
    Mitchell, Alex
    PSYCHO-ONCOLOGY, 2017, 26 : 131 - 132
  • [34] Olanzapine compared to fluphenazine in the treatment of acute schizophrenia
    Mimica, N
    Dossenbach, M
    Friedel, P
    Folnegovic-Smalc, V
    Makaric, G
    Jakovljevic, M
    Uglesic, B
    SCHIZOPHRENIA RESEARCH, 1998, 29 (1-2) : 150 - 150
  • [35] The Number Needed to Treat for All-Cause Medication Discontinuation in the Treatment of Schizophrenia: Consistency Across World Geographies and Study Designs
    Novick, D.
    Ascher-Svanum, H.
    Zhu, B.
    Brnabic, A.
    Stauffer, V.
    Peng, X.
    Karagianis, J.
    Perrin, E.
    PHARMACOPSYCHIATRY, 2010, 43 (03) : 81 - 85
  • [36] ANTIPSYCHOTICS FOR TREATMENT OF PEDIATRIC SCHIZOPHRENIA: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS OF SYMPTOM CONTROL, WEIGHT GAIN AND DISCONTINUATION DUE TO ADVERSE EVENTS
    Harvey, R. C.
    Shields, G. E.
    James, A. C.
    VALUE IN HEALTH, 2015, 18 (03) : A115 - A116
  • [37] Time to All-Cause Treatment Discontinuation as the Primary Outcome in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Study
    Davis, Sonia M.
    Stroup, T. Scott
    Koch, Gary G.
    Davis, Clarence E.
    Rosenheck, Robert A.
    Lieberman, Jeffrey A.
    STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2011, 3 (02): : 253 - 265
  • [38] Effects of olanzapine treatment on lipid profiles in patients with schizophrenia: a systematic review and meta-analysis
    Li, Rong
    Zhang, Yiqi
    Zhu, Wenqiang
    Ding, Chen
    Dai, Wenjie
    Su, Xin
    Dai, Wen
    Xiao, Jingmei
    Xing, Zhenhua
    Huang, Xiansheng
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [39] Effects of olanzapine treatment on lipid profiles in patients with schizophrenia: a systematic review and meta-analysis
    Rong Li
    Yiqi Zhang
    Wenqiang Zhu
    Chen Ding
    Wenjie Dai
    Xin Su
    Wen Dai
    Jingmei Xiao
    Zhenhua Xing
    Xiansheng Huang
    Scientific Reports, 10
  • [40] A comparison of olanzapine versus risperidone for the treatment of schizophrenia: a meta-analysis of randomised clinical trials
    Mudge, MAC
    Davey, PJ
    Coleman, KA
    Montgomery, W
    Croker, VS
    Mullen, K
    Castle, DJ
    INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE, 2005, 9 (01) : 3 - 15
12345